Literature DB >> 15181534

A novel genetic modifier of p53, mop1, results in embryonic lethality.

Susan C Evans1, Min Liang, Christopher Amos, Xiangjun Gu, Guillermina Lozano.   

Abstract

The heterogeneity that occurs in the tumor spectrum and latency in Li-Fraumeni syndrome (LFS) patients with inherited mutations in p53 suggest risk modifiers at loci other than the major gene. We developed a mouse model to investigate these risk modifiers. Inbred CE/J mice, which succumb to multiple types of tumors similar to those found in LFS, were crossed with the p53-null 129/Sv (129-Trp53(tm1Tyj)) mouse. In this cross, we uncovered evidence for a genetic modifier of p53, mop1, based on an unexpected mix of genotypes in the F2 progeny from Mendelian expectations. A model in which a recessive CE/J allele in combination with p53 heterozygosity or homozygosity results in lethality most closely fits the data. Using simple-sequence length polymorphism analysis of the entire genome, we identified a putative chromosomal region for this modifier of p53 on mouse chromosome 11 centromeric to p53.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15181534     DOI: 10.1007/s00335-004-2327-y

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  29 in total

1.  Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation.

Authors:  R Hakem; J L de la Pompa; A Elia; J Potter; T W Mak
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

Review 2.  The Li-Fraumeni syndrome: an inherited susceptibility to cancer.

Authors:  S C Evans; G Lozano
Journal:  Mol Med Today       Date:  1997-09

3.  Faster sequential genetic linkage computations.

Authors:  R W Cottingham; R M Idury; A A Schäffer
Journal:  Am J Hum Genet       Date:  1993-07       Impact factor: 11.025

4.  Partial rescue of the prophase I defects of Atm-deficient mice by p53 and p21 null alleles.

Authors:  C Barlow; M Liyanage; P B Moens; C X Deng; T Ried; A Wynshaw-Boris
Journal:  Nat Genet       Date:  1997-12       Impact factor: 38.330

5.  A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53.

Authors:  D S Lim; P Hasty
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

6.  Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk.

Authors:  Shih-Jen Hwang; Guillermina Lozano; Christopher I Amos; Louise C Strong
Journal:  Am J Hum Genet       Date:  2003-02-27       Impact factor: 11.025

7.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.

Authors:  S N Jones; A E Roe; L A Donehower; A Bradley
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

8.  Genetic background alters the spectrum of tumors that develop in p53-deficient mice.

Authors:  M Harvey; M J McArthur; C A Montgomery; A Bradley; L A Donehower
Journal:  FASEB J       Date:  1993-07       Impact factor: 5.191

9.  Tumor spectrum analysis in p53-mutant mice.

Authors:  T Jacks; L Remington; B O Williams; E M Schmitt; S Halachmi; R T Bronson; R A Weinberg
Journal:  Curr Biol       Date:  1994-01-01       Impact factor: 10.834

10.  A subset of p53-deficient embryos exhibit exencephaly.

Authors:  V P Sah; L D Attardi; G J Mulligan; B O Williams; R T Bronson; T Jacks
Journal:  Nat Genet       Date:  1995-06       Impact factor: 38.330

View more
  2 in total

1.  Genome-wide analysis of p53 under hypoxic conditions.

Authors:  Ester M Hammond; Daniel J Mandell; Ali Salim; Adam J Krieg; Thomas M Johnson; Haider A Shirazi; Laura D Attardi; Amato J Giaccia
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

2.  Genetic background influences tumour development in heterozygous Men1 knockout mice.

Authors:  Kate E Lines; Mahsa Javid; Anita A C Reed; Gerard V Walls; Mark Stevenson; Michelle Simon; Kreepa G Kooblall; Sian E Piret; Paul T Christie; Paul J Newey; Ann-Marie Mallon; Rajesh V Thakker
Journal:  Endocr Connect       Date:  2020-05       Impact factor: 3.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.